In addition to current clinical trials incorporating JAK inhibitors, our pre-clinical results support testing of FLT3 inhibitors for ETP-ALL with high FLT3 expression and/or FLT3-activating mutations. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.